During the corresponding time, Theratechnologies Inc recorded a revenue increase by 5.02 % year on year, While revenue at the Theratechnologies Inc 's corporate clients
Theratechnologies Inc's Comment on Sales, Marketing and Customers
The company sells EGRIFTA SV® primarily in the United States, generating revenues of $60.1 million, $53.7 million, and $50.5 million for fiscal years 2024, 2023, and 2022, respectively. EGRIFTA® was previously sold in the United States and Canada but was replaced by EGRIFTA SV® in the U.S. in 2020 and discontinued in Canada in October 2022. The company holds exclusive distribution agreements for EGRIFTA SV® under named patient programs in Latin America, the Middle East, North Africa, Turkey, Central and Eastern Europe, Western Europe, the Nordic Region, and the United Kingdom.
Trogarzo® has been commercialized solely in the United States since fiscal year 2022, with revenues of $25.7 million, $27.8 million, and $28.3 million for fiscal years 2024, 2023, and 2022, respectively. Trogarzo® was also sold in certain European countries until December 15, 2022, when commercialization rights were returned to TaiMed. The European Medicines Agency has withdrawn marketing approval of Trogarzo® in Europe. The company is responsible, but not obligated, to seek approval for Trogarzo® in Canada, with no filings made to date.
Customers and markets mentioned in filings include McKesson, TaiMed, and Theratechnologies Europe Limited.
: Theratechnologies has released preliminary tolerability and efficacy data from a Phase 1b, dose-ranging trial of Sudocetaxel Zendusortide, a therapeutic agent designed for patients with advanced ovarian cancer. The trial specifically focused on evaluating the safety profile and potential antitumor activity in heavily pre-treated patient populations. Ovarian cancer remains one of the most challenging malignancies to treat, particularly in patients with advanced disease who have undergone multiple lines of therapy. Sudocetaxel Zendusortide, an investigational agent, combines the cytotoxic properties of Sudocetaxel with a novel delivery method intended to enhance efficacy while minimizing systemic toxiciti...
Exploration of PROMISE-US Trial Design and Baseline Characteristics in the Study of Ibalizumab for HIV Patients with Multidrug Resistance The global struggle against HIV continues to challenge the scientific and medical communities, primarily due to the emergence of multidrug-resistant strains which constrain treatment options for heavily treatment-experienced individuals. Theratechnologies’ recent unveiling of the PROMISE-US trial design provides new insights into addressing these challenges by evaluating the efficacy and safety of Ibalizumab, a novel antiretroviral agent.Ibalizumab is a monoclonal antibody that inhibits viral entry into human cells by binding to the CD4 receptor, thus obstructing the pos...
The receipt of the CRL from the FDA is a significant step in the journey of tesamorelin s F8 formulation, which has been in a meticulous process of research and development by the company’s specialized team. The CRL is a procedural response from the FDA that outlines certain aspects that must be addressed for the sBLA to proceed. Theratechnologies, a company with a strong focus on the development and commercialization of innovative therapies, has affirmed its intent to address the FDA’s request and continue its pursuit of obtaining approval for this newer formulation of tesamorelin.Tesamorelin is a synthetic form of the growth hormone-releasing factor that stimulates the pituitary gland in the brain to ...
Theratechnologies Inc’s Comment on Sales, Marketing and Customers
The company sells EGRIFTA SV® primarily in the United States, generating revenues of $60.1 million, $53.7 million, and $50.5 million for fiscal years 2024, 2023, and 2022, respectively. EGRIFTA® was previously sold in the United States and Canada but was replaced by EGRIFTA SV® in the U.S. in 2020 and discontinued in Canada in October 2022. The company holds exclusive distribution agreements for EGRIFTA SV® under named patient programs in Latin America, the Middle East, North Africa, Turkey, Central and Eastern Europe, Western Europe, the Nordic Region, and the United Kingdom.
Trogarzo® has been commercialized solely in the United States since fiscal year 2022, with revenues of $25.7 million, $27.8 million, and $28.3 million for fiscal years 2024, 2023, and 2022, respectively. Trogarzo® was also sold in certain European countries until December 15, 2022, when commercialization rights were returned to TaiMed. The European Medicines Agency has withdrawn marketing approval of Trogarzo® in Europe. The company is responsible, but not obligated, to seek approval for Trogarzo® in Canada, with no filings made to date.
Customers and markets mentioned in filings include McKesson, TaiMed, and Theratechnologies Europe Limited.
Sources:
Theratechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Theratechnologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Theratechnologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.07 %